Insmed IncorporatedINSMNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank92
3Y CAGR+13.8%
5Y CAGR-10.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+13.8%/yr
vs +105.7%/yr prior
5Y CAGR
-10.4%/yr
Recent acceleration
Acceleration
-91.9pp
Decelerating
Percentile
P92
Near historical high
vs 5Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 36.74% |
| Q3 2025 | 5.21% |
| Q2 2025 | 16.13% |
| Q1 2025 | -15.11% |
| Q4 2024 | 19.18% |
| Q3 2024 | 2.77% |
| Q2 2024 | 21.20% |
| Q1 2024 | -11.64% |
| Q4 2023 | 25.54% |
| Q3 2023 | -44.59% |
| Q2 2023 | 54.04% |
| Q1 2023 | 2.49% |
| Q4 2022 | 24.92% |
| Q3 2022 | 12.82% |
| Q2 2022 | 4.94% |
| Q1 2022 | 10.48% |
| Q4 2021 | 8.54% |
| Q3 2021 | 8.80% |
| Q2 2021 | 5.32% |
| Q1 2021 | -9.47% |
| Q4 2020 | 63.76% |
| Q3 2020 | 15.84% |
| Q2 2020 | -1.20% |
| Q1 2020 | 10.89% |
| Q4 2019 | -4.98% |
| Q3 2019 | 2.39% |
| Q2 2019 | 7.48% |
| Q1 2019 | -21.85% |
| Q4 2018 | 0.98% |
| Q3 2018 | 10.68% |
| Q2 2018 | 18.69% |
| Q1 2018 | -11.34% |
| Q4 2017 | 27.27% |
| Q3 2017 | -0.73% |
| Q2 2017 | 20.75% |
| Q1 2017 | -59.44% |
| Q4 2016 | 134.16% |
| Q3 2016 | -1.83% |
| Q2 2016 | 16.18% |
| Q1 2016 | 4.59% |